SW
ATRA icon

SVB Wealth’s Atara Biotherapeutics ATRA Stock Holding History

SVB Wealth’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-421
Closed -$2.5K – 575
2025
Q1 		$2.5K Buy
+421
New +$3.67K ﹤0.01% 1184
2024
Q2 		– Sell
-843
Closed -$14.6K – 753
2024
Q1 		$14.6K Hold
843
– – ﹤0.01% 847
2023
Q4 		$10.8K Buy
843
+400
+90% +$9.33K ﹤0.01% 868
2023
Q3 		$16.4K Sell
443
-6,632
-94% -$295K ﹤0.01% 850
2023
Q2 		$285K Hold
7,075
– – 0.01% 696
2023
Q1 		$513K Sell
7,075
-1
-0% -$97 0.01% 527
2022
Q4 		$580K Sell
7,076
-5
-0.1% -$521 0.01% 525
2022
Q3 		$669K Buy
+7,081
New +$795K 0.01% 457

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SVB Wealth's ATRA Position: Q2 2025 in Review

SVB Wealth sold out of Atara Biotherapeutics (ATRA) in Q2 2025, closing a stake of 421 shares — an estimated $2.5K sold.

SVB Wealth first reported a position in ATRA in Q3 2022 and held it in 8 quarters. The position peaked at $669K in Q3 2022. 32 funds tracked by Wall St. Rank hold ATRA as of Q2 2025.

  • SVB Wealth reported no remaining Atara Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • SVB Wealth sold 421 Atara Biotherapeutics shares in Q2 2025, an estimated $2.5K.
  • SVB Wealth first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 8 quarters.
  • SVB Wealth's Atara Biotherapeutics position peaked at $669K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.